Investing.com - Chemomab Therapeutics DRC (NASDAQ: CMMB) reported first quarter EPS of $-0.04, in line with the analyst estimate of $-0.04. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Chemomab Therapeutics DRC's stock price closed at $1.64. It is down -20.77% in the last 3 months and down -36.43% in the last 12 months.
Chemomab Therapeutics DRC saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Chemomab Therapeutics DRC's stock price’s past reactions to earnings here.
According to InvestingPro, Chemomab Therapeutics DRC's Financial Health score is "weak performance".
Check out Chemomab Therapeutics DRC's recent earnings performance, and Chemomab Therapeutics DRC's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar